Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 213.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 345 shares of the company’s stock after buying an additional 235 shares during the period. Daiwa Securities Group Inc.’s holdings in Medpace were worth $105,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Contravisory Investment Management Inc. acquired a new position in Medpace during the fourth quarter worth about $26,000. RiverPark Advisors LLC purchased a new position in Medpace during the fourth quarter worth about $26,000. McGlone Suttner Wealth Management Inc. purchased a new position in Medpace during the fourth quarter worth about $33,000. FinTrust Capital Advisors LLC purchased a new position in Medpace during the third quarter worth about $30,000. Finally, IFP Advisors Inc raised its stake in Medpace by 144.3% during the third quarter. IFP Advisors Inc now owns 171 shares of the company’s stock worth $41,000 after purchasing an additional 101 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MEDP has been the topic of a number of analyst reports. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. Guggenheim lifted their target price on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research note on Wednesday. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and lifted their target price for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Finally, UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $443.00.

Insiders Place Their Bets

In other Medpace news, VP Susan E. Burwig sold 102 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares in the company, valued at approximately $6,117,943. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Medpace news, Director Ashley M. Keating sold 250 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the sale, the director now directly owns 250 shares in the company, valued at approximately $102,467.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Susan E. Burwig sold 102 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now owns 15,181 shares in the company, valued at $6,117,943. The disclosure for this sale can be found here. Insiders have sold a total of 189,340 shares of company stock worth $76,651,647 in the last ninety days. 20.30% of the stock is owned by corporate insiders.

Medpace Stock Performance

Shares of MEDP stock opened at $395.93 on Friday. The firm’s 50 day moving average price is $397.83 and its 200-day moving average price is $325.70. Medpace Holdings, Inc. has a one year low of $189.30 and a one year high of $421.00. The firm has a market cap of $12.27 billion, a P/E ratio of 40.36, a P/E/G ratio of 1.94 and a beta of 1.38.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. During the same period in the prior year, the business posted $2.27 EPS. The business’s revenue for the quarter was up 17.7% compared to the same quarter last year. As a group, research analysts predict that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.